Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares Repurchased
Ratios

Pharma-Bio Serv (PBSV) Cost of Revenue (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Cost of Revenue readings, the most recent being $1.6 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue fell 7.67% to $1.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was $6.0 million, a 13.01% decrease, with the full-year FY2025 number at $6.1 million, down 12.9% from a year prior.
  • Cost of Revenue hit $1.6 million in Q1 2026 for Pharma-Bio Serv, up from $1.4 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.8 million in Q1 2022 to a low of $1.4 million in Q3 2025.
  • Median Cost of Revenue over the past 5 years was $1.8 million (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Cost of Revenue: grew 18.95% in 2022 and later crashed 45.31% in 2024.
  • Pharma-Bio Serv's Cost of Revenue stood at $3.5 million in 2022, then dropped by 24.4% to $2.7 million in 2023, then tumbled by 39.79% to $1.6 million in 2024, then fell by 12.82% to $1.4 million in 2025, then rose by 12.27% to $1.6 million in 2026.
  • The last three reported values for Cost of Revenue were $1.6 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025) per Business Quant data.